Abstract
The development of antiretroviral agents that disrupt the early interaction between Human immunodeficiency virus type-1 (HIV-1) and host cells offers an attractive alternative to therapies targeting viral enzymes. In this study, we evaluate arylsulfonyl phenols, a diarylsulfone subclass, as small-molecule CD4 antagonists that inhibit the envelope glycoprotein 120 (gp120) using combined in silico and in vitro approaches. Designed to occupy the hydrophobic Phe43 cavity and adjacent β20/21 region of gp120, these compounds show enhanced drug-likeness, balanced polarity, high membrane permeability, and improved predicted oral bioavailability relative to the attachment inhibitor fostemsavir. Molecular docking and MM GBSA analyses identified 5o, 5m, 5e, 5a, 5j, 4b, and 4d as high affinity compounds with favourable predicted gp120 binding scores of −7.52 to −8.26 kcal/mol and ΔGbind values of −49.71 to −56.14 kcal/mol, exceeding those of fostemsavir and the reference CD4 antagonist NBD-11021. Fifty-nanosecond molecular dynamics simulations further supported stable gp120-ligand complexes for 5o, 5m, 5a, and 5j. In vitro antiviral assays in C8166 cells demonstrated potent activity, with EC50 values of 0.0162–0.2130 μM and high therapeutic indices (TI); notably, 5a (EC50 = 0.0162 μM, TI = 162,839.51) and 5m (EC50 = 0.0238 μM, TI = 124,159.66) showed antiviral potencies approaching zidovudine (AZT). In this study, we investigated arylsulfonyl phenols, a diarylsulfone subclass, as potential small-molecule inhibitors of HIV-1 entry targeting the gp120–CD4 interaction using integrated computational and in-vitro approaches and highlight 5a and 5m as candidates for further optimization as next-generation attachment blockers.